Scroll to the Bottom of this Information to Begin this Course
Translational Landscape of Cell Therapy for AML: CARs and Beyond – Module 4
Jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.
The educational portion of this activity is supported by independent educational grants from Amgen Inc., AstraZeneca Pharmaceuticals LP, and Bristol-Myers Squibb Company. Additional funding provided by The Leukemia & Lymphoma Society.
Release date: March 27, 2020
Valid through: March 26, 2021
Specialty: Hematology, Oncology
Estimated Time to Complete Activity: 30 minutes
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
This activity will provide learners with the latest developments in translational medicine for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.
Upon completion of this activity, participants should be better able to:
- Describe the latest advances in translational medicine for patients with acute myeloid leukemia (AML)
- Explain how novel genetic screening strategies currently in development may be used to identify patients at risk of developing hematologic malignancies and direct early intervention strategies
- Identify novel treatment strategies that may improve patient quality of life by reducing the toxicity of treatment and prolonging disease control
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Catherine M. Bollard, MD, FRACP, FRCPA
Bosworth Chair for Cancer Biology
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine
Director, Center for Cancer and Immunology Research
Director, Program for Cell Enhancement and Technologies for Immunotherapy
Children’s National Health System
The George Washington University School of Medicine and Health Sciences
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, The Leukemia & Lymphoma Society, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Catherine M. Bollard, MD, FRACP, FRCPA, has affiliations with Cellectis (Consulting Fees); Caballetta, Neximmune, Torque (Ownership Interest less than 5%); Mana (Ownership Interest greater than 5%, SAB); Patent on HIV T cells (Receipt of Intellectual Property Rights/Patent Holder).
Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose. The Leukemia & Lymphoma Society planners and managers have nothing to disclose.
Instructions for Participation and Credit
There is no fee for this educational activity.
During the period March 27, 2020 through March 26, 2021, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the evaluation form. Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records.
Please contact Postgraduate Institute for Medicine Continuing Medical Education Department at email@example.com or by calling 303-799-1930.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.